{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:42:00Z","timestamp":1792460520531,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["109915\/Z\/15\/Z"],"award-info":[{"award-number":["109915\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["201064\/Z\/16\/Z"],"award-info":[{"award-number":["201064\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N025431\/1"],"award-info":[{"award-number":["MR\/N025431\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V009346\/1"],"award-info":[{"award-number":["MR\/V009346\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/S005021\/1"],"award-info":[{"award-number":["MR\/S005021\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["309548"],"award-info":[{"award-number":["309548"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010897","name":"Newton Fund","doi-asserted-by":"publisher","award":["MR\/N027302\/1"],"award-info":[{"award-number":["MR\/N027302\/1"]}],"id":[{"id":"10.13039\/100010897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002927","name":"Addenbrooke's Charitable Trust, Cambridge University Hospitals","doi-asserted-by":"publisher","award":["G100142"],"award-info":[{"award-number":["G100142"]}],"id":[{"id":"10.13039\/501100002927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004282","name":"Evelyn Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022186","name":"Lily Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022186","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","award":["BRC-1215-20014"],"award-info":[{"award-number":["BRC-1215-20014"]}],"id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"crossref","award":["FDN-167281"],"award-info":[{"award-number":["FDN-167281"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000223","name":"Muscular Dystrophy Canada","doi-asserted-by":"publisher","award":["Network Catalyst Grant for NMD4C"],"award-info":[{"award-number":["Network Catalyst Grant for NMD4C"]}],"id":[{"id":"10.13039\/501100000223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["CFI-JELF 38412"],"award-info":[{"award-number":["CFI-JELF 38412"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["950-232279"],"award-info":[{"award-number":["950-232279"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Inherited defects of the neuromuscular junction (NMJ) comprise an increasingly diverse range of diseases. Several recently identified genes highlight the overlap between peripheral neuropathies and congenital myasthenic syndromes (CMS). The beta-2 adrenergic receptor agonist salbutamol has been shown to provide symptomatic benefit in CMS, while improving structural defects at the NMJ. Based on these findings, we identified cases of motor neuropathy with NMJ dysfunction and assessed the effect of salbutamol on motor function.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cases of motor neuropathy with significant NMJ dysfunction, were identified using repetitive nerve stimulation and single fibre electromyography. Oral salbutamol was administered for 12\u00a0months. Repeat neurophysiological and clinical assessments were undertaken at baseline, 6\u00a0months and 12\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Significant defects of neuromuscular transmission were identified in 15 patients harbouring a range of genetic defects, including mutations in <jats:italic>GARS1, DNM2, SYT2<\/jats:italic> and <jats:italic>DYNC1H<\/jats:italic>. No clear benefit on motor function was seen following the administration of 12\u00a0months of oral salbutamol; however, there was a significant improvement in patient reported fatigue. In addition, no clear effect on neurophysiological parameters was seen in patients treated with salbutamol. Side-effects due to off-target beta-adrenergic effects were significant in the patient cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These results highlight the involvement of the NMJ in several subtypes of motor neuropathies, including subtypes of neuropathy due to deficits in mitochondrial fusion-fission, synaptic vesicle transport, calcium channels and tRNA synthetases. Whether the NMJ dysfunction is simply due to muscle reinnervation or a pathology unrelated to denervation is unknown. The involvement of the NMJ may represent a novel therapeutic target in these conditions. However, treatment regimens will need to be more targeted for patients with primary inherited defects of neuromuscular transmission.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-023-11643-z","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T11:02:32Z","timestamp":1677927752000},"page":"3112-3119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Neuromuscular junction involvement in inherited motor neuropathies: genetic heterogeneity and effect of oral salbutamol treatment"],"prefix":"10.1007","volume":"270","author":[{"given":"Grace","family":"McMacken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger G.","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Wake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns","family":"Lochmuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9841-170X","authenticated-orcid":false,"given":"Rita","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,4]]},"reference":[{"issue":"Pt 7","key":"11643_CR1","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1093\/brain\/123.7.1516","volume":"123","author":"KM Krajewski","year":"2000","unstructured":"Krajewski KM, Lewis RA, Fuerst DR et al (2000) Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain J Neurol 123(Pt 7):1516\u20131527. https:\/\/doi.org\/10.1093\/brain\/123.7.1516","journal-title":"Brain J Neurol"},{"issue":"16","key":"11643_CR2","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1212\/01.wnl.0000327643.05073.eb","volume":"71","author":"AJ Videler","year":"2008","unstructured":"Videler AJ, van Dijk JP, Beelen A, de Visser M, Nollet F, van Schaik IN (2008) Motor axon loss is associated with hand dysfunction in Charcot-Marie-Tooth disease 1a. Neurology 71(16):1254\u20131260. https:\/\/doi.org\/10.1212\/01.wnl.0000327643.05073.eb","journal-title":"Neurology"},{"issue":"9","key":"11643_CR3","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1097\/NEN.0b013e3181efa658","volume":"69","author":"N Vavlitou","year":"2010","unstructured":"Vavlitou N, Sargiannidou I, Markoullis K, Kyriacou K, Scherer SS, Kleopa KA (2010) Axonal pathology precedes demyelination in a mouse model of X-linked demyelinating\/ type I Charcot-Marie tooth (CMT1X) neuropathy. J Neuropathol Exp Neurol 69(9):945\u2013958. https:\/\/doi.org\/10.1097\/NEN.0b013e3181efa658","journal-title":"J Neuropathol Exp Neurol"},{"issue":"7668","key":"11643_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature23484","volume":"548","author":"Q Zhou","year":"2017","unstructured":"Zhou Q, Zhou P, Wang AL et al (2017) The primed SNARE-complexin-synaptotagmin complex for neuronal exocytosis. Nature 548(7668):420\u2013425. https:\/\/doi.org\/10.1038\/nature23484","journal-title":"Nature"},{"issue":"22","key":"11643_CR5","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1212\/WNL.0000000000002185","volume":"85","author":"RG Whittaker","year":"2015","unstructured":"Whittaker RG, Herrmann DN, Bansagi B et al (2015) Electrophysiologic features of SYT2 mutations causing a treatable neuromuscular syndrome. Neurology 85(22):1964\u20131971. https:\/\/doi.org\/10.1212\/WNL.0000000000002185","journal-title":"Neurology"},{"issue":"3","key":"11643_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ajhg.2014.08.007","volume":"95","author":"DN Herrmann","year":"2014","unstructured":"Herrmann DN, Horvath R, Sowden JE et al (2014) Synaptotagmin 2 mutations cause an autosomal-dominant form of lambert-eaton myasthenic syndrome and nonprogressive motor neuropathy. Am J Hum Genet 95(3):332\u2013339. https:\/\/doi.org\/10.1016\/j.ajhg.2014.08.007","journal-title":"Am J Hum Genet"},{"issue":"10","key":"11643_CR7","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/ajmg.a.61765","volume":"182","author":"S Donkervoort","year":"2020","unstructured":"Donkervoort S, Mohassel P, Laugwitz L et al (2020) Biallelic loss of function variants in SYT2 cause a treatable congenital onset presynaptic myasthenic syndrome. Am J Med Genet A 182(10):2272\u20132283. https:\/\/doi.org\/10.1002\/ajmg.a.61765","journal-title":"Am J Med Genet A"},{"issue":"2","key":"11643_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/mus.27332","volume":"64","author":"RA Maselli","year":"2021","unstructured":"Maselli RA, Wei DT, Hodgson TS et al (2021) Dominant and recessive congenital myasthenic syndromes caused by SYT2 mutations. Muscle Nerve 64(2):219\u2013224. https:\/\/doi.org\/10.1002\/mus.27332","journal-title":"Muscle Nerve"},{"key":"11643_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2016.06.033","author":"S Bauch\u00e9","year":"2016","unstructured":"Bauch\u00e9 S, O\u2019Regan S, Azuma Y et al (2016) Impaired presynaptic high-affinity choline transporter causes a congenital myasthenic syndrome with episodic apnea. Am J Hum Genet. https:\/\/doi.org\/10.1016\/j.ajhg.2016.06.033","journal-title":"Am J Hum Genet"},{"issue":"10","key":"11643_CR10","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/humu.23828","volume":"40","author":"M Banerjee","year":"2019","unstructured":"Banerjee M, Arutyunov D, Brandwein D et al (2019) The novel p.Ser263Phe mutation in the human high-affinity choline transporter 1 (CHT1\/SLC5A7) causes a lethal form of fetal akinesia syndrome. Hum Mutat 40(10):1676\u20131683. https:\/\/doi.org\/10.1002\/humu.23828","journal-title":"Hum Mutat"},{"issue":"10","key":"11643_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.nmd.2018.06.020","volume":"28","author":"JM Pardal-Fern\u00e1ndez","year":"2018","unstructured":"Pardal-Fern\u00e1ndez JM, Carrascosa-Romero MC, \u00c1lvarez S, Medina-Monz\u00f3n MC, Caama\u00f1o MB, de Cabo C (2018) A new severe mutation in the SLC5A7 gene related to congenital myasthenic syndrome type 20. Neuromuscul Disord 28(10):881\u2013884. https:\/\/doi.org\/10.1016\/j.nmd.2018.06.020","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"11643_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.nmd.2020.10.006","volume":"31","author":"PM Rodr\u00edguez Cruz","year":"2021","unstructured":"Rodr\u00edguez Cruz PM, Hughes I, Manzur A et al (2021) Presynaptic congenital myasthenic syndrome due to three novel mutations in SLC5A7 encoding the sodium-dependant high-affinity choline transporter. Neuromuscul Disord 31(1):21\u201328. https:\/\/doi.org\/10.1016\/j.nmd.2020.10.006","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"11643_CR13","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1212\/NXG.0000000000000222","volume":"4","author":"CG Salter","year":"2018","unstructured":"Salter CG, Beijer D, Hardy H et al (2018) Truncating SLC5A7 mutations underlie a spectrum of dominant hereditary motor neuropathies. Neurol Genet 4(2):e222. https:\/\/doi.org\/10.1212\/NXG.0000000000000222","journal-title":"Neurol Genet"},{"issue":"2","key":"11643_CR14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/cge.13369","volume":"94","author":"K Hamanaka","year":"2018","unstructured":"Hamanaka K, Takahashi K, Miyatake S et al (2018) Confirmation of SLC5A7-related distal hereditary motor neuropathy 7 in a family outside Wales. Clin Genet 94(2):274\u2013275. https:\/\/doi.org\/10.1111\/cge.13369","journal-title":"Clin Genet"},{"issue":"9","key":"11643_CR15","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1093\/hmg\/ddy062","volume":"27","author":"G McMacken","year":"2018","unstructured":"McMacken G, Cox D, Roos A, M\u00fcller J, Whittaker R, Lochm\u00fcller H (2018) The beta-adrenergic agonist salbutamol modulates neuromuscular junction formation in zebrafish models of human myasthenic syndromes. Hum Mol Genet 27(9):1556\u20131564. https:\/\/doi.org\/10.1093\/hmg\/ddy062","journal-title":"Hum Mol Genet"},{"issue":"14","key":"11643_CR16","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1093\/hmg\/ddz059","volume":"28","author":"GM McMacken","year":"2019","unstructured":"McMacken GM, Spendiff S, Whittaker RG et al (2019) Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome. Hum Mol Genet 28(14):2339\u20132351. https:\/\/doi.org\/10.1093\/hmg\/ddz059","journal-title":"Hum Mol Genet"},{"issue":"12","key":"11643_CR17","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1093\/brain\/awz322","volume":"142","author":"AE Vanhaesebrouck","year":"2019","unstructured":"Vanhaesebrouck AE, Webster R, Maxwell S et al (2019) \u03b22-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure. Brain J Neurol 142(12):3713\u20133727. https:\/\/doi.org\/10.1093\/brain\/awz322","journal-title":"Brain J Neurol"},{"issue":"3","key":"11643_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1529-8027.2011.00350.x","volume":"16","author":"SM Murphy","year":"2011","unstructured":"Murphy SM, Herrmann DN, McDermott MP et al (2011) Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst JPNS 16(3):191\u2013198. https:\/\/doi.org\/10.1111\/j.1529-8027.2011.00350.x","journal-title":"J Peripher Nerv Syst JPNS"},{"issue":"1","key":"11643_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/ene.14514","volume":"28","author":"G McMacken","year":"2021","unstructured":"McMacken G, Whittaker RG, Charlton R, Barresi R, Lochm\u00fcller H, Horvath R (2021) Inherited neuropathies with predominant upper limb involvement: genetic heterogeneity and overlapping pathologies. Eur J Neurol 28(1):297\u2013304. https:\/\/doi.org\/10.1111\/ene.14514","journal-title":"Eur J Neurol"},{"issue":"12","key":"11643_CR20","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1093\/brain\/awp251","volume":"132","author":"C Verhamme","year":"2009","unstructured":"Verhamme C, van Schaik IN, Koelman JHTM, de Haan RJ, de Visser M (2009) The natural history of Charcot\u2013Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain 132(12):3252\u20133262. https:\/\/doi.org\/10.1093\/brain\/awp251","journal-title":"Brain"},{"issue":"8","key":"11643_CR21","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1136\/jnnp-2014-308826","volume":"86","author":"V Fridman","year":"2015","unstructured":"Fridman V, Bundy B, Reilly MM et al (2015) CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis. J Neurol Neurosurg Psychiatry 86(8):873\u2013878. https:\/\/doi.org\/10.1136\/jnnp-2014-308826","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11643_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102092","author":"V Cappello","year":"2017","unstructured":"Cappello V, Francolini M (2017) Neuromuscular junction dismantling in amyotrophic lateral sclerosis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18102092","journal-title":"Int J Mol Sci"},{"key":"11643_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fnana.2016.00006","volume":"10","author":"M Boido","year":"2016","unstructured":"Boido M, Vercelli A (2016) Neuromuscular junctions as key contributors and therapeutic targets in spinal muscular atrophy. Front Neuroanat 10:6. https:\/\/doi.org\/10.3389\/fnana.2016.00006","journal-title":"Front Neuroanat"},{"issue":"6","key":"11643_CR24","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/mus.26676","volume":"60","author":"S Nicolau","year":"2019","unstructured":"Nicolau S, Kao JC, Liewluck T (2019) Trouble at the junction: When myopathy and myasthenia overlap. Muscle Nerve 60(6):648\u2013657. https:\/\/doi.org\/10.1002\/mus.26676","journal-title":"Muscle Nerve"},{"issue":"2","key":"11643_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1212\/CPJ.0000000000000795","volume":"11","author":"LP Braz","year":"2021","unstructured":"Braz LP, Ng YS, Gorman GS et al (2021) Neuromuscular junction abnormalities in mitochondrial disease: an observational cohort study. Neurol Clin Pract 11(2):97\u2013104. https:\/\/doi.org\/10.1212\/CPJ.0000000000000795","journal-title":"Neurol Clin Pract"},{"issue":"2","key":"11643_CR26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ajhg.2011.07.002","volume":"89","author":"MN Weedon","year":"2011","unstructured":"Weedon MN, Hastings R, Caswell R et al (2011) Exome sequencing identifies a DYNC1H1 mutation in a large pedigree with dominant axonal Charcot-Marie-Tooth disease. Am J Hum Genet 89(2):308\u2013312. https:\/\/doi.org\/10.1016\/j.ajhg.2011.07.002","journal-title":"Am J Hum Genet"},{"issue":"10","key":"11643_CR27","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1093\/hmg\/ddt659","volume":"23","author":"JN Sleigh","year":"2014","unstructured":"Sleigh JN, Grice SJ, Burgess RW, Talbot K, Cader MZ (2014) Neuromuscular junction maturation defects precede impaired lower motor neuron connectivity in Charcot\u2013Marie\u2013Tooth type 2D mice. Hum Mol Genet 23(10):2639\u20132650. https:\/\/doi.org\/10.1093\/hmg\/ddt659","journal-title":"Hum Mol Genet"},{"issue":"7","key":"11643_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-02798-y","volume":"11","author":"JN Sleigh","year":"2020","unstructured":"Sleigh JN, Mech AM, Schiavo G (2020) Developmental demands contribute to early neuromuscular degeneration in CMT2D mice. Cell Death Dis 11(7):1\u201310. https:\/\/doi.org\/10.1038\/s41419-020-02798-y","journal-title":"Cell Death Dis"},{"issue":"11","key":"11643_CR29","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1523\/JNEUROSCI.1762-15.2016","volume":"36","author":"EL Spaulding","year":"2016","unstructured":"Spaulding EL, Sleigh JN, Morelli KH, Pinter MJ, Burgess RW, Seburn KL (2016) Synaptic deficits at neuromuscular junctions in two mouse models of Charcot-Marie-Tooth type 2d. J Neurosci 36(11):3254\u20133267. https:\/\/doi.org\/10.1523\/JNEUROSCI.1762-15.2016","journal-title":"J Neurosci"},{"issue":"5620","key":"11643_CR30","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1126\/science.1083129","volume":"300","author":"M Hafezparast","year":"2003","unstructured":"Hafezparast M, Klocke R, Ruhrberg C et al (2003) Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 300(5620):808\u2013812. https:\/\/doi.org\/10.1126\/science.1083129","journal-title":"Science"},{"key":"11643_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016753","author":"SL Courchesne","year":"2011","unstructured":"Courchesne SL, Pazyra-Murphy MF, Lee DJ, Segal RA (2011) Neuromuscular Junction Defects in Mice with Mutation of dynein heavy chain 1. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0016753","journal-title":"PLoS ONE"},{"issue":"6","key":"11643_CR32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00109-013-0994-4","volume":"91","author":"EM Gibbs","year":"2013","unstructured":"Gibbs EM, Clarke NF, Rose K et al (2013) Neuromuscular junction abnormalities in DNM2-related centronuclear myopathy. J Mol Med Berl Ger 91(6):727\u2013737. https:\/\/doi.org\/10.1007\/s00109-013-0994-4","journal-title":"J Mol Med Berl Ger"},{"issue":"24","key":"11643_CR33","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1093\/hmg\/ddz249","volume":"28","author":"X Massana Mu\u00f1oz","year":"2019","unstructured":"Massana Mu\u00f1oz X, Buono S, Koebel P, Laporte J, Cowling BS (2019) Different in vivo impacts of dynamin 2 mutations implicated in Charcot-Marie-Tooth neuropathy or centronuclear myopathy. Hum Mol Genet 28(24):4067\u20134077. https:\/\/doi.org\/10.1093\/hmg\/ddz249","journal-title":"Hum Mol Genet"},{"issue":"2","key":"11643_CR34","doi-asserted-by":"publisher","first-page":"e000164","DOI":"10.1136\/bmjno-2021-000164","volume":"3","author":"WD Arnold","year":"2021","unstructured":"Arnold WD, Severyn S, Zhao S et al (2021) Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen. BMJ Neurol Open 3(2):e000164. https:\/\/doi.org\/10.1136\/bmjno-2021-000164","journal-title":"BMJ Neurol Open"},{"key":"11643_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fneur.2020.00101","volume":"11","author":"L Shang","year":"2020","unstructured":"Shang L, Chu H, Lu Z (2020) Can the large-scale decrement in repetitive nerve stimulation be used as an exclusion criterion for amyotrophic lateral sclerosis? Front Neurol 11:101. https:\/\/doi.org\/10.3389\/fneur.2020.00101","journal-title":"Front Neurol"},{"issue":"7","key":"11643_CR36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.nmd.2019.04.003","volume":"29","author":"AL Frongia","year":"2019","unstructured":"Frongia AL, Natera-de Benito D, Ortez C et al (2019) Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II. Neuromuscul Disord 29(7):517\u2013524. https:\/\/doi.org\/10.1016\/j.nmd.2019.04.003","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"11643_CR37","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1249\/MSS.0b013e3182951d2d","volume":"45","author":"N Decorte","year":"2013","unstructured":"Decorte N, Bachasson D, Guinot M et al (2013) Effect of salbutamol on neuromuscular function in endurance athletes. Med Sci Sports Exerc 45(10):1925\u20131932. https:\/\/doi.org\/10.1249\/MSS.0b013e3182951d2d","journal-title":"Med Sci Sports Exerc"},{"issue":"2","key":"11643_CR38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/thx.52.2.136","volume":"52","author":"DW Evans","year":"1997","unstructured":"Evans DW, Salome CM, King GG, Rimmer SJ, Seale JP, Woolcock AJ (1997) Effect of regular inhaled salbutamol on airway responsiveness and airway inflammation in rhinitic non-asthmatic subjects. Thorax 52(2):136\u2013142","journal-title":"Thorax"},{"issue":"Suppl 3","key":"11643_CR39","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1016\/j.nmd.2012.10.016","volume":"22","author":"GM Ramdharry","year":"2012","unstructured":"Ramdharry GM, Thornhill A, Mein G, Reilly MM, Marsden JF (2012) Exploring the experience of fatigue in people with Charcot-Marie-Tooth disease. Neuromuscul Disord NMD 22(Suppl 3):S208-213. https:\/\/doi.org\/10.1016\/j.nmd.2012.10.016","journal-title":"Neuromuscul Disord NMD"},{"issue":"4","key":"11643_CR40","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S1474-4422(11)70025-4","volume":"10","author":"D Pareyson","year":"2011","unstructured":"Pareyson D, Reilly MM, Schenone A et al (2011) Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 10(4):320\u2013328. https:\/\/doi.org\/10.1016\/S1474-4422(11)70025-4","journal-title":"Lancet Neurol"},{"issue":"5781","key":"11643_CR41","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1126\/science.1127142","volume":"312","author":"K Okada","year":"2006","unstructured":"Okada K, Inoue A, Okada M et al (2006) The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 312(5781):1802\u20131805. https:\/\/doi.org\/10.1126\/science.1127142","journal-title":"Science"},{"issue":"6203","key":"11643_CR42","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1126\/science.1250744","volume":"345","author":"S Arimura","year":"2014","unstructured":"Arimura S, Okada T, Tezuka T et al (2014) Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction. Science 345(6203):1505\u20131508. https:\/\/doi.org\/10.1126\/science.1250744","journal-title":"Science"},{"issue":"7","key":"11643_CR43","doi-asserted-by":"publisher","first-page":"880","DOI":"10.15252\/emmm.201607298","volume":"9","author":"S Miyoshi","year":"2017","unstructured":"Miyoshi S, Tezuka T, Arimura S, Tomono T, Okada T, Yamanashi Y (2017) DOK7 gene therapy enhances motor activity and life span in ALS model mice. EMBO Mol Med 9(7):880\u2013889. https:\/\/doi.org\/10.15252\/emmm.201607298","journal-title":"EMBO Mol Med"},{"key":"11643_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fncel.2018.00017","volume":"12","author":"M Boido","year":"2018","unstructured":"Boido M, De Amicis E, Valsecchi V et al (2018) Increasing Agrin function antagonizes muscle atrophy and motor impairment in spinal muscular atrophy. Front Cell Neurosci 12:17. https:\/\/doi.org\/10.3389\/fncel.2018.00017","journal-title":"Front Cell Neurosci"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11643-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11643-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11643-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T17:07:15Z","timestamp":1684256835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11643-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,4]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["11643"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11643-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,4]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest and the publication has not been submitted to any other journal. Dr. Grace McMacken reports no disclosures. Dr. Roger Whittaker reports no disclosures. Ruth Wake reports no disclosures. Dr. Hanns Lochm\u00fcller reports no disclosures. Dr. Rita Horvath reports no disclosures. The Authors have no financial or non-financial interests that are directly or indirectly related to the work submitted for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All human and animal studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard statement"}}]}}